Assessing the relationship between systemic immune-inflammation index and mortality in patients with hypertrophic cardiomyopathy
Authors:
Open Access
- 3 December 2021
- journal article
- research article
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 126 (1)
Abstract
Background: This study investigates the predictive value of the systemic immune-inflammation index (SII), which was calculated as platelet × neutrophil/lymphocyte ratio, for all-cause mortality in patients with hypertrophic cardiomyopathy (HCM). Methods: A total of 360 HCM patients were enrolled. They were divided into three groups based on the tertiles of baseline SII. The association between SII and all-cause mortality was analyzed. Results: There were 53 HCM patients who died during a mean follow-up time of 4.8 years (min: 6 days and max: 10.8 years), and the mortality rate was 3.0 per 100 person years. The cumulative mortality rate was significantly different among the three tertiles of SII (P = 0.004), and the mortality rate in tertile 3 was much higher than that in the first two tertiles. In reference to tertile 1, the fully adjusted hazard ratios of all-cause mortality were 1.02 for the tertile 2 (95% confidence interval [CI]: 0.45–2.31, P = 0.966) and 2.31 for tertile 3 (95% CI: 1.10–4.87, P = 0.027). No significant interactions between SII and other variables were observed during subgroup analysis. The discriminative power was better for mid-term outcome than that for short-term or long-term outcomes. Sensitivity analyses including patients with normal platelet and white blood cell count have revealed similar results. Conclusion: SII was a significant risk factor for all-cause mortality in HCM patients. However, the discriminative power was poor to moderate. It could be used in combination with other risk factors in mortality risk stratification in HCM.Keywords
This publication has 32 references indexed in Scilit:
- Prognostic Significance of Plasma High‐Sensitivity C‐Reactive Protein in Patients With Hypertrophic CardiomyopathyJournal of the American Heart Association, 2017
- Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasivenessScientific Reports, 2017
- Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management StrategiesJACC, 2015
- New Perspectives on the Prevalence of Hypertrophic CardiomyopathyJACC, 2015
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular CarcinomaClinical Cancer Research, 2014
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathyEuropean Heart Journal, 2014
- Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathyHeart, 2012
- Inflammation and immune surveillance in cancerSeminars in Cancer Biology, 2012
- Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediatorsSeminars in Cancer Biology, 2006
- Historical trends in reported survival rates in patients with hypertrophic cardiomyopathyHeart, 2005